:format(webp)/cdn.mskdoctors.com/storage/2026/6/o9WdvvTEMjoLykyJDcS9IhpAmqUc9qzq.jpg)
ChondroFiller injection after tibial plateau fractureCartilage damage from tibial plateau fractures does not repair itself, leading to progressive joint wear. ChondroFiller, a collagen scaffold injected under ultrasound, recruits the patient's own cells to generate hyaline-like repair tissue; three-year data show functional improvement of 32.4 points, exceeding the threshold for meaningful clinical benefit.Cartilage damage from tibial plateau fractures does not repair itself, leading to progressive joint wear. ChondroFiller, a collagen scaffold injected under ultrasound, recruits the patient's own cells to generate hyaline-like repair tissue; three-year data show functional improvement of 32.4 points, exceeding the threshold for meaningful clinical benefit.
:format(webp)/cdn.mskdoctors.com/storage/2026/6/yIAGZGajyWr3EcFixjxB4VUoZIzQlkDg.jpg)
ChondroFiller injection vs knee replacementChondroFiller is a collagen scaffold injection that recruits the patient's own repair cells to treat focal cartilage defects. Knee replacement suits end-stage, widespread wear; the choice between them depends on imaging findings, not age.ChondroFiller is a collagen scaffold injection that recruits the patient's own repair cells to treat focal cartilage defects. Knee replacement suits end-stage, widespread wear; the choice between them depends on imaging findings, not age.
:format(webp)/cdn.mskdoctors.com/storage/2026/6/Lj6L1IaL5TBE3CuCl6wA8ci1T5bHoA72.jpg)
ChondroFiller success rates in practiceChondroFiller, which recruits a patient's own cells to fill cartilage defects, produces meaningful pain reduction and improved joint function in 70–85% of patients within one to five years; but success depends on selecting younger patients with focal defects in otherwise healthy joints.ChondroFiller, which recruits a patient's own cells to fill cartilage defects, produces meaningful pain reduction and improved joint function in 70–85% of patients within one to five years; but success depends on selecting younger patients with focal defects in otherwise healthy joints.
